Bottom Line Up Front
MSCs' immunomodulatory properties make them a subject of legitimate research for autoimmune conditions including multiple sclerosis, lupus, rheumatoid arthritis, and Crohn's disease. Published case series report encouraging results, but this is early-stage evidence (Level 3–4). Patients should continue established immunosuppressive therapies and consult their managing physician before pursuing MSC treatment.
Evidence Level: Level 3–4
Published case series and small cohort studies with encouraging results. No completed Phase III randomized controlled trials. This is an area of active research, not established clinical practice.
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues. MSCs have demonstrated the ability to modulate immune responses in laboratory studies and animal models, suppressing overactive immune pathways while preserving normal immune function. This has generated significant interest in MSC therapy for autoimmune conditions.
Critical Warning
MSC therapy for autoimmune disease should complement, not replace, your current treatment regimen. Do not discontinue immunosuppressive medications, biologics, or disease-modifying drugs without your managing physician's guidance. The evidence supporting MSC therapy for autoimmune conditions is early-stage and should not be treated as a proven alternative to established treatments.
Exploring MSC Therapy for an Autoimmune Condition?
We'll connect you with a clinic that coordinates with your existing medical team and sets honest expectations based on the current evidence.
Get Free Consultation